UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 79

Sortiert nach

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes

The New England journal of medicine, 2018-05, Vol.378 (20), p.1908-1919

2018

Volltextzugriff (PDF)

First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor

Clinical and translational science, 2024-05, Vol.17 (5), p.e13789-n/a

2024

Volltextzugriff (PDF)

Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation

Transplant international, 2012-05, Vol.25 (5), p.592-602

2012

Volltextzugriff (PDF)

Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy

Kidney international reports, 2023-12, Vol.8 (12), p.2754-2764

2023

Volltextzugriff (PDF)

P789: EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN (IPTA) MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATED WITH THE ANTI‐C5 MONOCLONAL ANTIBODY (MAB) TESIDOLUMAB (TESI)

HemaSphere, 2023-08, Vol.7 (S3), p.e17022e8-n/a

2023

Volltextzugriff (PDF)

Adult onset Still’s disease—The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)

Seminars in arthritis and rheumatism, 2017-10, Vol.47 (2), p.295-302

2017

Volltextzugriff (PDF)

Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy

Clinical and experimental nephrology, 2014-02, Vol.18 (1), p.135-143

2014

Volltextzugriff (PDF)

3278 HUMAN PHARMACOKINETICS OF MULTIPLE, STEADY-STATE DOSING OF IPTACOPAN

Nephrology, dialysis, transplantation, 2023-06, Vol.38 (Supplement_1)

2023

Volltextzugriff (PDF)

4463 JAPANESE AND WHITES SHARE SIMILAR IPTACOPAN PHARMACOKINETICS AND PHARMACODYNAMICS

Nephrology, dialysis, transplantation, 2023-06, Vol.38 (Supplement_1)

2023

Volltextzugriff (PDF)

Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride

Nephrology (Carlton, Vic.), 2011-11, Vol.16 (8), p.743-750

2011

Volltextzugriff (PDF)

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

The Lancet (British edition), 2022-01, Vol.399 (10320), p.161-171

2022

Volltextzugriff (PDF)

4447 EFFECT OF RENAL IMPAIRMENT ON IPTACOPAN PHARMACOKINETICS

Nephrology, dialysis, transplantation, 2023-06, Vol.38 (Supplement_1)

2023

Volltextzugriff (PDF)

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

Kidney international, 2024-01, Vol.105 (1), p.189-199

2024

Volltextzugriff (PDF)

Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study

Transplantation, 2015-07, Vol.99 (7), p.1455

2015

Volltextzugriff (PDF)

WCN24-555 PHARMACOKINETICS OF SINGLE DOSES OF IPTACOPAN

Kidney international reports, 2024-04, Vol.9 (4), p.S111-S112

2024

Volltextzugriff (PDF)

Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity

Pediatric rheumatology online journal, 2015-11, Vol.13 (47), p.50-50, Article 50

2015

Volltextzugriff (PDF)

MO042LNP023: A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR FOR THE TREATMENT OF GLOMERULAR DISEASE

Nephrology, dialysis, transplantation, 2020-06, Vol.35 (Supplement_3)

2020

Volltextzugriff (PDF)

12-Month Analysis of a Phase 2 Study of Iptacopan (LNP023) Monotherapy for Paroxysmal Nocturnal Hemoglobinuria

Blood, 2021-11, Vol.138 (Supplement 1), p.2173-2173

2021

Volltextzugriff (PDF)

Dose-Exposure-Response Relationships of Biomarkers and Efficacy Measures with Iptacopan, a Complement Factor B Inhibitor, in Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) with or without Concomitant Anti-C5 Therapy

Blood, 2022-11, Vol.140 (Supplement 1), p.5803-5804

2022

Volltextzugriff (PDF)

Effect of Iptacopan on Proteinuria and Complement Biomarkers Over Time in IgA Nephropathy: FR-OR59

Journal of the American Society of Nephrology, 2022-11, Vol.33 (11S), p.33-34

2022

Volltextzugriff (PDF)

12M Interim Analysis of an Open-Label, Non-Randomized Extension of a Phase 2 Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Iptacopan in Subjects With C3G: TH-PO505

Journal of the American Society of Nephrology, 2022-11, Vol.33 (11S), p.190-190

2022

Volltextzugriff (PDF)

Open‐Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome

Arthritis & rheumatology (Hoboken, N.J.), 2017-08, Vol.69 (8), p.1679-1688

2017

Volltextzugriff (PDF)

FC 036IPTACOPAN (LNP023): A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY AND EFFECTIVELY STABILISES EGFR IN C3 GLOMERULOPATHY

Nephrology, dialysis, transplantation, 2021-05, Vol.36 (Supplement_1)

2021

Volltextzugriff (PDF)

Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial

The Lancet. Haematology, 2021-05, Vol.8 (5), p.e344-e354

2021

Volltextzugriff (PDF)

WCN24-550 SINGLE DOSE OF IPTACOPAN TREATMENT RAPIDLY DESCREASES PLASMA COMPLEMENT Bb LEVELS

Kidney international reports, 2024-04, Vol.9 (4), p.S111-S111

2024

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(73)

Publikationsform

Sprache

Englisch
(54)
Deutsch
(24)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes

First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor

Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation

Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy

P789: EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN (IPTA) MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATED WITH THE ANTI‐C5 MONOCLONAL ANTIBODY (MAB) TESIDOLUMAB (TESI)

Adult onset Still’s disease—The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)

Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy

3278 HUMAN PHARMACOKINETICS OF MULTIPLE, STEADY-STATE DOSING OF IPTACOPAN

4463 JAPANESE AND WHITES SHARE SIMILAR IPTACOPAN PHARMACOKINETICS AND PHARMACODYNAMICS

Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

4447 EFFECT OF RENAL IMPAIRMENT ON IPTACOPAN PHARMACOKINETICS

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study

WCN24-555 PHARMACOKINETICS OF SINGLE DOSES OF IPTACOPAN

Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity

MO042LNP023: A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR FOR THE TREATMENT OF GLOMERULAR DISEASE

12-Month Analysis of a Phase 2 Study of Iptacopan (LNP023) Monotherapy for Paroxysmal Nocturnal Hemoglobinuria

Dose-Exposure-Response Relationships of Biomarkers and Efficacy Measures with Iptacopan, a Complement Factor B Inhibitor, in Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) with or without Concomitant Anti-C5 Therapy

Effect of Iptacopan on Proteinuria and Complement Biomarkers Over Time in IgA Nephropathy: FR-OR59

12M Interim Analysis of an Open-Label, Non-Randomized Extension of a Phase 2 Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Iptacopan in Subjects With C3G: TH-PO505

Open‐Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome

FC 036IPTACOPAN (LNP023): A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY AND EFFECTIVELY STABILISES EGFR IN C3 GLOMERULOPATHY

Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial

WCN24-550 SINGLE DOSE OF IPTACOPAN TREATMENT RAPIDLY DESCREASES PLASMA COMPLEMENT Bb LEVELS

Suchergebnisse filtern